Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596830 · ClinicalTrials.gov registry record · Phase 3
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 681
- Enrollment target
NCT00596830: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00596830 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 681 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00596830, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 681 participants
- Enrollment target
Study Summary
Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.
Primary Outcome
Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG CP-751,871 (Figitumumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 681 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Why NCT00596830 stopped before completion
NCT00596830 is an interventional study that assigns participants to a tested intervention. The registered 681 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00596830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00596830 about?
NCT00596830 is a clinical study titled "Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology". Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.
What is the current status of trial NCT00596830?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 681 participants. The study started on 2008-04. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00596830?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), CP-751,871 (Figitumumab) (DRUG).
Who is sponsoring clinical trial NCT00596830?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00596830's enrollment target sits among peer trials
681 530th of 2000 higher than 1,469 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05382559 · 681 participants · Phase 1
A Study of ASP3082 in Adults With Advanced Solid Tumors
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia